Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610951 | 0.93 | ESR1 (0.47) | ESR1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL20425286 | 0.93 | ESR1 (0.47) | ESR1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL30610954 | 0.90 | ESR1 (0.60) | ESR1ESR2 | |
| SCHEMBL20425311 | 0.90 | ESR1 (0.60) | ESR1ESR2 | |
| SCHEMBL7936824 | 0.86 | ESR1 (0.56) | ESR1ESR2TDP1 | |
| SCHEMBL7944332 | 0.83 | TUBB4A (0.49) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL7352370 | 0.82 | MEN1 (0.51) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL8637183 | 0.79 | ESR1 (0.60) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL7946164 | 0.79 | ESR1 (0.52) | ESR1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4508297 | 0.77 | ESR1 (0.36) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6258826-B1 | HALOGEN SUBSTITUTED BENZOTHIOPHENE COMPOUNDS WITH CARRIERS | ELI LILLY AND COMPANY | 2001-07-10 | — | — | US | claimed |
| US-6087378-A | THE ACTIVE BENZO(B)THIOPHENE COMPOUNDS FOR TREATING OSTEOPOROSIS AND CARDIOVASCULAR DISORDERS, ESPECIALLY HYPERLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2000-07-11 | — | — | US | claimed |
| EP-3016947-B1 | BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-09-05 | — | — | EP | disclosed |
| US-9988376-B2 | Benzothiophene derivatives as estrogen receptor inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-05 | — | — | US | disclosed |
| US-9988376-B2 | Benzothiophene derivatives as estrogen receptor inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-05 | — | — | US | disclosed |
| US-20160368911-A1 | BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160368911-A1 | BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160368911-A1 | BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | US | disclosed |
| EP-3016947-A1 | BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015000867-A1 | BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-01-08 | — | — | WO | disclosed |
| US-6258826-B1 | HALOGEN SUBSTITUTED BENZOTHIOPHENE COMPOUNDS WITH CARRIERS | ELI LILLY AND COMPANY | 2001-07-10 | — | — | US | disclosed |
| US-6087378-A | THE ACTIVE BENZO(B)THIOPHENE COMPOUNDS FOR TREATING OSTEOPOROSIS AND CARDIOVASCULAR DISORDERS, ESPECIALLY HYPERLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368911-A1 | BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS | ESR1, GPER1, ESR2 | ESR1 1/4885HDAC3 1565/4885HDAC1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.